GAITHERSBURG, Md. & BOSTON–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing personalized yet off the shelf immunotherapies for cancer and infectious diseases, today announced the appointment of Anu Hoey as Chief Business Officer, responsible for leading business and corporate development.

“With over 18 years of transactional and corporate expertise, Anu will be instrumental as we work to advance our pipeline and execute on our vision of establishing a new and disruptive class of immunotherapies.”

Tweet this

“We are thrilled to welcome Anu to our team to help drive our strategic growth. Her business development experience and industry knowledge are a strong addition to Sensei as we prepare to grow our platform and pipeline in the coming months,” said John Celebi, CEO of Sensei Biotherapeutics. “With over 18 years of transactional and corporate expertise, Anu will be instrumental as we work to advance our pipeline and execute on our vision of establishing a new and disruptive class of immunotherapies.”

“Sensei’s unique ImmunoPhage platform represents a promising, differentiated strategy to cancer treatment, designed to induce all elements of a robust anti-tumor immune response,” said Anu Hoey, Chief Business Officer of Sensei Biotherapeutics. “This is a very exciting time in Sensei’s development and I look forward to working alongside this accomplished management team to lead the company’s corporate strategy and further evolve the company into its next stage of growth.”

Prior to joining Sensei, Ms. Hoey served as Chief Business Officer at Second Genome, where she played an integral role in the company’s corporate development strategy and led the execution of a multi-year strategic transaction with Gilead. Prior to Second Genome, Ms. Hoey worked at Invenra, Arcus Biosciences and Sutro Biopharma, in executive roles of increasing responsibility and executed multiple strategic transactions with major pharmaceutical companies, including Celgene, EMD Serono and Exelixis. She holds a B.S. in Molecular Genetics from The Ohio State University, a M.S. in Molecular Virology from Case Western Reserve University and a M.B.A. from the University of San Francisco.

About Sensei Biotherapeutics

Sensei Biotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of personalized yet off the shelf immunotherapies. The company has developed a unique phage-based platform, ImmunoPhage™, that enables the rapid generation of immune activating agents that fully engage the immune system. The platform enables efficient, scalable and cost-effective manufacturing to support all clinical programs. Sensei’s diversified pipeline focuses on antibody-based therapeutic and vaccine treatments for various cancer indications. Its most advanced program, SNS-301, a vaccine targeting Aspartyl beta Hydroxylase (ASPH) in advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN), is currently enrolling patients in Phase 2 clinical trials. Its earlier stage programs include SNS-401, a vaccine cocktail for the treatment of Merkel Cell Carcinoma and SNS-VISTA, antibody-based therapeutic targeting V-domain Ig suppressor of T cell activation (VISTA). The company brings together scientific leaders in biology, immunology, and oncology along with a highly experienced management team and scientific advisors. For more information, please visit www.senseibio.com.

Forward-looking statements

This press release may contain certain forward-looking statements, including with respect to the clinical development and potential benefits of Sensei’s product candidates and the strategic growth of Sensei’s platform and pipeline. Although Sensei believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond Sensei’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could”, and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond Sensei’s control that could cause Sensei’s actual results, performance, or achievements to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements. Except as required by law, Sensei assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Contacts

Media Contact:
Kathryn Morris
The Yates Network
914-204-6412
kathryn@theyatesnetwork.com

Investor Contact:
Julie Seidel
Stern Investor Relations, Inc.
212-362-1200
julie.seidel@sternir.com